Healthcare technology company ResMed's (NYSE: RMD) stock wasn't quite the picture of health on Wednesday. The shares lost ...

Shares of ResMed Inc. RMD inched 0.81% higher to $244.94 Friday, on what proved to be an all-around mixed trading session for ...

Key Takeaways The S&P 500 ended 0.3% lower on Wednesday, Sept. 18, as the Federal Reserve announced its first interest-rate ...

ResMed Inc. closed $4.30 below its 52-week high ($255.18), which the company reached on September 9th.

Major U.S. indexes were little changed at midday Wednesday, ahead of the Federal Reserve's decision on interest rates.

ResMed achieved double-digit revenue growth through acquisitions and operating efficiencies, with improving capital ...

ResMed's AirSense 11 platform and myAir app enhance patient engagement and efficiency. Check out why I remain bullish on RMD ...

ResMed faces a 3% drop in share price after concerns over Eli Lilly’s Ozempic, which could impact the demand for CPAP ...

Polark's pessimism stems from concerns that Resmed might be poised to lose market share to its pharmaceutical rival Eli Lilly ...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to ...

Wolfe Research analyst Michael Polark downgraded the rating on Resmed (RMD – Research Report) to a Sell yesterday, setting a price target ...

In a report released today, Michael Matson from Needham maintained a Hold rating on Resmed (RMD – Research Report). The company’s ...